231 related articles for article (PubMed ID: 22792389)
1. Effect of genetic variation in STXBP5 and STX2 on von Willebrand factor and bleeding phenotype in type 1 von Willebrand disease patients.
van Loon JE; Sanders YV; de Wee EM; Kruip MJ; de Maat MP; Leebeek FW
PLoS One; 2012; 7(7):e40624. PubMed ID: 22792389
[TBL] [Abstract][Full Text] [Related]
2. CLEC4M and STXBP5 gene variations contribute to von Willebrand factor level variation in von Willebrand disease.
Sanders YV; van der Bom JG; Isaacs A; Cnossen MH; de Maat MP; Laros-van Gorkom BA; Fijnvandraat K; Meijer K; van Duijn CM; Mauser-Bunschoten EP; Eikenboom J; Leebeek FW;
J Thromb Haemost; 2015 Jun; 13(6):956-66. PubMed ID: 25832887
[TBL] [Abstract][Full Text] [Related]
3. Effect of genetic variations in syntaxin-binding protein-5 and syntaxin-2 on von Willebrand factor concentration and cardiovascular risk.
van Loon JE; Leebeek FW; Deckers JW; Dippel DW; Poldermans D; Strachan DP; Tang W; O'Donnell CJ; Smith NL; de Maat MP
Circ Cardiovasc Genet; 2010 Dec; 3(6):507-12. PubMed ID: 21156930
[TBL] [Abstract][Full Text] [Related]
4. Genetic Variation in the Syntaxin-Binding Protein STXBP5 in Type 1 von Willebrand Disease Patients.
Lind-Halldén C; Manderstedt E; Carlberg D; Lethagen S; Halldén C
Thromb Haemost; 2018 Aug; 118(8):1382-1389. PubMed ID: 29972863
[TBL] [Abstract][Full Text] [Related]
5. Performance related factors are the main determinants of the von Willebrand factor response to exhaustive physical exercise.
van Loon JE; Sonneveld MA; Praet SF; de Maat MP; Leebeek FW
PLoS One; 2014; 9(3):e91687. PubMed ID: 24626470
[TBL] [Abstract][Full Text] [Related]
6. Associations of multiple genetic variations with plasma levels of Von Willebrand Factor and clinical phenotype in Iranian patients with Von Willebrand disease type 1.
Zafarani A; Tabibian S; Barati M; Ghodratnia E; Safa M
Transfus Apher Sci; 2023 Oct; 62(5):103766. PubMed ID: 37550093
[TBL] [Abstract][Full Text] [Related]
7. Determinants of bleeding phenotype in adult patients with moderate or severe von Willebrand disease.
de Wee EM; Sanders YV; Mauser-Bunschoten EP; van der Bom JG; Degenaar-Dujardin ME; Eikenboom J; de Goede-Bolder A; Laros-van Gorkom BA; Meijer K; Hamulyák K; Nijziel MR; Fijnvandraat K; Leebeek FW;
Thromb Haemost; 2012 Oct; 108(4):683-92. PubMed ID: 22918553
[TBL] [Abstract][Full Text] [Related]
8. Changes in von Willebrand factor level and von Willebrand activity with age in type 1 von Willebrand disease.
Rydz N; Grabell J; Lillicrap D; James PD
Haemophilia; 2015 Sep; 21(5):636-41. PubMed ID: 25756206
[TBL] [Abstract][Full Text] [Related]
9. Comorbidities associated with higher von Willebrand factor (VWF) levels may explain the age-related increase of VWF in von Willebrand disease.
Atiq F; Meijer K; Eikenboom J; Fijnvandraat K; Mauser-Bunschoten EP; van Galen KPM; Nijziel MR; Ypma PF; de Meris J; Laros-van Gorkom BAP; van der Bom JG; de Maat MP; Cnossen MH; Leebeek FWG;
Br J Haematol; 2018 Jul; 182(1):93-105. PubMed ID: 29767844
[TBL] [Abstract][Full Text] [Related]
10. Novel Thrombotic Function of a Human SNP in STXBP5 Revealed by CRISPR/Cas9 Gene Editing in Mice.
Zhu QM; Ko KA; Ture S; Mastrangelo MA; Chen MH; Johnson AD; O'Donnell CJ; Morrell CN; Miano JM; Lowenstein CJ
Arterioscler Thromb Vasc Biol; 2017 Feb; 37(2):264-270. PubMed ID: 28062498
[TBL] [Abstract][Full Text] [Related]
11. Whole blood ristocetin-induced platelet impedance aggregometry does not reflect clinical severity in patients with type 1 von Willebrand disease.
Nakajima Y; Nogami K; Yada K; Ogiwara K; Furukawa S; Shimonishi N; Shima M
Haemophilia; 2019 May; 25(3):e174-e179. PubMed ID: 30866149
[TBL] [Abstract][Full Text] [Related]
12. The role of genetics in the pathogenesis and diagnosis of type 1 Von Willebrand disease.
Flood VH; Garcia J; Haberichter SL
Curr Opin Hematol; 2019 Sep; 26(5):331-335. PubMed ID: 31261173
[TBL] [Abstract][Full Text] [Related]
13. Unraveling the Influence of Common von Willebrand factor variants on von Willebrand Disease Phenotype: An Exploratory Study on the Molecular and Clinical Profile of von Willebrand Disease in Spain Cohort.
Borràs N; Garcia-Martínez I; Batlle J; Pérez-Rodríguez A; Parra R; Altisent C; López-Fernández MF; Costa Pinto J; Batlle-López F; Cid AR; Bonanad S; Cabrera N; Moret A; Mingot-Castellano ME; Navarro N; Pérez-Montes R; Marcellini S; Moreto A; Herrero S; Soto I; Fernández-Mosteirín N; Jiménez-Yuste V; Alonso N; de Andrés-Jacob A; Fontanes E; Campos R; Paloma MJ; Bermejo N; Berrueco R; Mateo J; Arribalzaga K; Marco P; Palomo Á; Castro Quismondo N; Iñigo B; Del Mar Nieto M; Vidal R; Martínez MP; Aguinaco R; Tenorio M; Ferreiro M; García-Frade J; Rodríguez-Huerta AM; Cuesta J; Rodríguez-González R; García-Candel F; Dobón M; Aguilar C; Corrales I; Vidal F
Thromb Haemost; 2020 Mar; 120(3):437-448. PubMed ID: 32135566
[TBL] [Abstract][Full Text] [Related]
14. Discrepant platelet and plasma von Willebrand factor in von Willebrand disease patients with p.Pro2808Leufs*24.
Bowman ML; Pluthero FG; Tuttle A; Casey L; Li L; Christensen H; Robinson KS; Lillicrap D; Kahr WHA; James P
J Thromb Haemost; 2017 Jul; 15(7):1403-1411. PubMed ID: 28453889
[TBL] [Abstract][Full Text] [Related]
15. Bleeding Symptoms and von Willebrand Factor Levels: 30-Year Experience in a Tertiary Care Center.
Moonla C; Akkawat B; Kittikalayawong Y; Sukperm A; Meesanun M; Uaprasert N; Sosothikul D; Rojnuckarin P
Clin Appl Thromb Hemost; 2019; 25():1076029619866916. PubMed ID: 31359769
[TBL] [Abstract][Full Text] [Related]
16. Genome-wide association studies identify genetic loci for low von Willebrand factor levels.
van Loon J; Dehghan A; Weihong T; Trompet S; McArdle WL; Asselbergs FW; Chen MH; Lopez LM; Huffman JE; Leebeek FW; Basu S; Stott DJ; Rumley A; Gansevoort RT; Davies G; Wilson JJ; Witteman JC; Cao X; de Craen AJ; Bakker SJ; Psaty BM; Starr JM; Hofman A; Wouter Jukema J; Deary IJ; Hayward C; van der Harst P; Lowe GD; Folsom AR; Strachan DP; Smith N; de Maat MP; O'Donnell C
Eur J Hum Genet; 2016 Jul; 24(7):1035-40. PubMed ID: 26486471
[TBL] [Abstract][Full Text] [Related]
17. Clinical significance of slightly reduced von Willebrand factor activity.
Bykowska K; Ceglarek B
Pol Arch Intern Med; 2020 Mar; 130(3):225-231. PubMed ID: 31990275
[TBL] [Abstract][Full Text] [Related]
18. von Willebrand disease and aging: an evolving phenotype.
Sanders YV; Giezenaar MA; Laros-van Gorkom BA; Meijer K; van der Bom JG; Cnossen MH; Nijziel MR; Ypma PF; Fijnvandraat K; Eikenboom J; Mauser-Bunschoten EP; Leebeek FW;
J Thromb Haemost; 2014 Jul; 12(7):1066-75. PubMed ID: 24750783
[TBL] [Abstract][Full Text] [Related]
19. Bleeding tendency and efficacy of anti-haemorrhagic treatments in patients with type 1 von Willebrand disease and increased von Willebrand factor clearance.
Castaman G; Tosetto A; Federici AB; Rodeghiero F
Thromb Haemost; 2011 Apr; 105(4):647-54. PubMed ID: 21264446
[TBL] [Abstract][Full Text] [Related]
20. Clinical and laboratory variability in a cohort of patients diagnosed with type 1 VWD in the United States.
Flood VH; Christopherson PA; Gill JC; Friedman KD; Haberichter SL; Bellissimo DB; Udani RA; Dasgupta M; Hoffmann RG; Ragni MV; Shapiro AD; Lusher JM; Lentz SR; Abshire TC; Leissinger C; Hoots WK; Manco-Johnson MJ; Gruppo RA; Boggio LN; Montgomery KT; Goodeve AC; James PD; Lillicrap D; Peake IR; Montgomery RR
Blood; 2016 May; 127(20):2481-8. PubMed ID: 26862110
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
